Effect of allergic bronchopulmonary aspergillosis on FEV 1 in children and adolescents with cystic fibrosis: A European Cystic Fibrosis Society Patient Registry analysis

Athanasios G. Kaditis, Michael Miligkos, Anna Bossi, Carla Colombo, Elpis Hatziagorou, Nataliya Kashirskaya, Isabelle De Monestrol, Muriel Thomas, Meir Mei-Zahav, George Chrousos, Anna Zolin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective To evaluate the effect of allergic bronchopulmonary aspergillosis (ABPA) on FEV 1 percent predicted in children and adolescents with cystic fibrosis. Design Longitudinal data analysis (2008-2010). Setting Patients participating in the European Cystic Fibrosis Society Patient Registry. Participants 3350 patients aged 6-17 years. Main outcome measure FEV 1 percent predicted was the main outcome measure (one measurement per year per child). To describe the effect of ABPA (main explanatory variable) on FEV 1 while controlling for other prognostic factors, a linear mixed effects regression model was applied. Results In 2008, the mean (±SD) FEV 1 percent predicted was 78.6 (±20.6) in patients with ABPA (n=346) and 88 (±19.8) in those without ABPA (n=2806). After considering other variables, FEV 1 in subjects with ABPA on entry to the study was 1.47 percentage points lower than FEV 1 in patients of similar age without ABPA (p=0.003). There was no FEV 1 decline associated with ABPA over the subsequent study years as the interaction of ABPA with age was not significant (p>0.05). For patients aged 11.82 years (population mean age), poor body mass index had the greatest impact on FEV 1 in 2008, followed by high-risk genotype (two severe mutations), female gender, diabetes mellitus, chronic Pseudomonas aeruginosa infection and ABPA in descending order of effect size. Conclusions In contrast to the common clinical belief of ABPA having a serious impact on lung function, the difference in FEV 1 between young patients with and without the complication was found to be modest when the effect of other prognostic factors was considered.

Original languageEnglish
Pages (from-to)742-747
Number of pages6
JournalArchives of Disease in Childhood
Volume102
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Allergic Bronchopulmonary Aspergillosis
Cystic Fibrosis
Registries
Outcome Assessment (Health Care)
Pseudomonas Infections
Pseudomonas aeruginosa
Diabetes Mellitus
Body Mass Index
Genotype

Keywords

  • allergic bronchopulmonary aspergillosis
  • cystic fibrosis
  • lung function

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effect of allergic bronchopulmonary aspergillosis on FEV 1 in children and adolescents with cystic fibrosis : A European Cystic Fibrosis Society Patient Registry analysis. / Kaditis, Athanasios G.; Miligkos, Michael; Bossi, Anna; Colombo, Carla; Hatziagorou, Elpis; Kashirskaya, Nataliya; De Monestrol, Isabelle; Thomas, Muriel; Mei-Zahav, Meir; Chrousos, George; Zolin, Anna.

In: Archives of Disease in Childhood, Vol. 102, No. 8, 01.08.2017, p. 742-747.

Research output: Contribution to journalArticle

Kaditis, AG, Miligkos, M, Bossi, A, Colombo, C, Hatziagorou, E, Kashirskaya, N, De Monestrol, I, Thomas, M, Mei-Zahav, M, Chrousos, G & Zolin, A 2017, 'Effect of allergic bronchopulmonary aspergillosis on FEV 1 in children and adolescents with cystic fibrosis: A European Cystic Fibrosis Society Patient Registry analysis', Archives of Disease in Childhood, vol. 102, no. 8, pp. 742-747. https://doi.org/10.1136/archdischild-2016-311132
Kaditis, Athanasios G. ; Miligkos, Michael ; Bossi, Anna ; Colombo, Carla ; Hatziagorou, Elpis ; Kashirskaya, Nataliya ; De Monestrol, Isabelle ; Thomas, Muriel ; Mei-Zahav, Meir ; Chrousos, George ; Zolin, Anna. / Effect of allergic bronchopulmonary aspergillosis on FEV 1 in children and adolescents with cystic fibrosis : A European Cystic Fibrosis Society Patient Registry analysis. In: Archives of Disease in Childhood. 2017 ; Vol. 102, No. 8. pp. 742-747.
@article{d7704cd2454a474b9c1074eaa2d59ce5,
title = "Effect of allergic bronchopulmonary aspergillosis on FEV 1 in children and adolescents with cystic fibrosis: A European Cystic Fibrosis Society Patient Registry analysis",
abstract = "Objective To evaluate the effect of allergic bronchopulmonary aspergillosis (ABPA) on FEV 1 percent predicted in children and adolescents with cystic fibrosis. Design Longitudinal data analysis (2008-2010). Setting Patients participating in the European Cystic Fibrosis Society Patient Registry. Participants 3350 patients aged 6-17 years. Main outcome measure FEV 1 percent predicted was the main outcome measure (one measurement per year per child). To describe the effect of ABPA (main explanatory variable) on FEV 1 while controlling for other prognostic factors, a linear mixed effects regression model was applied. Results In 2008, the mean (±SD) FEV 1 percent predicted was 78.6 (±20.6) in patients with ABPA (n=346) and 88 (±19.8) in those without ABPA (n=2806). After considering other variables, FEV 1 in subjects with ABPA on entry to the study was 1.47 percentage points lower than FEV 1 in patients of similar age without ABPA (p=0.003). There was no FEV 1 decline associated with ABPA over the subsequent study years as the interaction of ABPA with age was not significant (p>0.05). For patients aged 11.82 years (population mean age), poor body mass index had the greatest impact on FEV 1 in 2008, followed by high-risk genotype (two severe mutations), female gender, diabetes mellitus, chronic Pseudomonas aeruginosa infection and ABPA in descending order of effect size. Conclusions In contrast to the common clinical belief of ABPA having a serious impact on lung function, the difference in FEV 1 between young patients with and without the complication was found to be modest when the effect of other prognostic factors was considered.",
keywords = "allergic bronchopulmonary aspergillosis, cystic fibrosis, lung function",
author = "Kaditis, {Athanasios G.} and Michael Miligkos and Anna Bossi and Carla Colombo and Elpis Hatziagorou and Nataliya Kashirskaya and {De Monestrol}, Isabelle and Muriel Thomas and Meir Mei-Zahav and George Chrousos and Anna Zolin",
year = "2017",
month = "8",
day = "1",
doi = "10.1136/archdischild-2016-311132",
language = "English",
volume = "102",
pages = "742--747",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Effect of allergic bronchopulmonary aspergillosis on FEV 1 in children and adolescents with cystic fibrosis

T2 - A European Cystic Fibrosis Society Patient Registry analysis

AU - Kaditis, Athanasios G.

AU - Miligkos, Michael

AU - Bossi, Anna

AU - Colombo, Carla

AU - Hatziagorou, Elpis

AU - Kashirskaya, Nataliya

AU - De Monestrol, Isabelle

AU - Thomas, Muriel

AU - Mei-Zahav, Meir

AU - Chrousos, George

AU - Zolin, Anna

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objective To evaluate the effect of allergic bronchopulmonary aspergillosis (ABPA) on FEV 1 percent predicted in children and adolescents with cystic fibrosis. Design Longitudinal data analysis (2008-2010). Setting Patients participating in the European Cystic Fibrosis Society Patient Registry. Participants 3350 patients aged 6-17 years. Main outcome measure FEV 1 percent predicted was the main outcome measure (one measurement per year per child). To describe the effect of ABPA (main explanatory variable) on FEV 1 while controlling for other prognostic factors, a linear mixed effects regression model was applied. Results In 2008, the mean (±SD) FEV 1 percent predicted was 78.6 (±20.6) in patients with ABPA (n=346) and 88 (±19.8) in those without ABPA (n=2806). After considering other variables, FEV 1 in subjects with ABPA on entry to the study was 1.47 percentage points lower than FEV 1 in patients of similar age without ABPA (p=0.003). There was no FEV 1 decline associated with ABPA over the subsequent study years as the interaction of ABPA with age was not significant (p>0.05). For patients aged 11.82 years (population mean age), poor body mass index had the greatest impact on FEV 1 in 2008, followed by high-risk genotype (two severe mutations), female gender, diabetes mellitus, chronic Pseudomonas aeruginosa infection and ABPA in descending order of effect size. Conclusions In contrast to the common clinical belief of ABPA having a serious impact on lung function, the difference in FEV 1 between young patients with and without the complication was found to be modest when the effect of other prognostic factors was considered.

AB - Objective To evaluate the effect of allergic bronchopulmonary aspergillosis (ABPA) on FEV 1 percent predicted in children and adolescents with cystic fibrosis. Design Longitudinal data analysis (2008-2010). Setting Patients participating in the European Cystic Fibrosis Society Patient Registry. Participants 3350 patients aged 6-17 years. Main outcome measure FEV 1 percent predicted was the main outcome measure (one measurement per year per child). To describe the effect of ABPA (main explanatory variable) on FEV 1 while controlling for other prognostic factors, a linear mixed effects regression model was applied. Results In 2008, the mean (±SD) FEV 1 percent predicted was 78.6 (±20.6) in patients with ABPA (n=346) and 88 (±19.8) in those without ABPA (n=2806). After considering other variables, FEV 1 in subjects with ABPA on entry to the study was 1.47 percentage points lower than FEV 1 in patients of similar age without ABPA (p=0.003). There was no FEV 1 decline associated with ABPA over the subsequent study years as the interaction of ABPA with age was not significant (p>0.05). For patients aged 11.82 years (population mean age), poor body mass index had the greatest impact on FEV 1 in 2008, followed by high-risk genotype (two severe mutations), female gender, diabetes mellitus, chronic Pseudomonas aeruginosa infection and ABPA in descending order of effect size. Conclusions In contrast to the common clinical belief of ABPA having a serious impact on lung function, the difference in FEV 1 between young patients with and without the complication was found to be modest when the effect of other prognostic factors was considered.

KW - allergic bronchopulmonary aspergillosis

KW - cystic fibrosis

KW - lung function

UR - http://www.scopus.com/inward/record.url?scp=85025160988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025160988&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2016-311132

DO - 10.1136/archdischild-2016-311132

M3 - Article

AN - SCOPUS:85025160988

VL - 102

SP - 742

EP - 747

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 8

ER -